Pneumonia News and Research

Latest Pneumonia News and Research

Wildfire exposure may increase risk of heart failure

An EPA study published online Monday in Environmental Health Perspectives finds that the 2008 peat bog wildfires in NC led to an increase in emergency room visits for respiratory and cardiovascular effects.

28 Jun 2011

Researchers identify new component of plague causing bacterium that can be used as a vaccine

Researchers from the Smiley lab at the Trudeau Institute have now identified a single component of the plague causing bacterium that can be used as a vaccine. This single "subunit" could potentially be used to create a safer form of a T cell-stimulating plague vaccine. The new data is featured in the July issue of The Journal of Immunology.

27 Jun 2011

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Over a decade ago, Canadian patients diagnosed with chronic myeloid leukemia (CML), celebrated when PrGleevec (imatinib mesylate) was approved in Canada.

27 Jun 2011

'Copilots' for physicians in intensive care units could reduce mortality rates

Caring for patients in a medical intensive care unit in a hospital and flying a 747 are complicated tasks that require tracking thousands of important details, some of which could get overlooked. That's why the pilot has a checklist and a copilot to make sure nothing slips by.

23 Jun 2011

U.S. FDA approves generic Levaquin for treatment of bacterial infections

The U.S. Food and Drug Administration today approved the first generic versions of Levaquin, an antibiotic approved to treat certain infections in people ages 18 and older.

21 Jun 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech, a member of the Roche Group, announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

Serious RSV infections may occur in previously healthy infants and children

For most parents, respiratory syncytial virus (RSV) isn't a familiar term. But it's a common cause of serious respiratory infections with a major impact on the health of infants and young children worldwide, according to a special CDC Review Article in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jun 2011

High proportion of men with prostate cancer die from the disease

Up to half the number of men with prostate cancer who die do so as a direct result of the disease, rather than from other causes according to a new study presented at the National Cancer Intelligence Network conference in London.

15 Jun 2011

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.

15 Jun 2011

Billions committed for children’s vaccines

British Prime Minister David Cameron has pledged £814m to help vaccinate children around the world against preventable diseases like pneumonia. He made the announcement at a summit in London where countries are being asked to give an extra £2.3bn ($3.7bn) by 2015 for child vaccines. He said, “Three children die every minute from pneumonia alone. Waiting is not the right thing to do and I don't think that 0.7 per cent of our gross national income is too high a price to pay for saving lives.”

13 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

MinuteClinic, the retail health care division of CVS Caremark, and OhioHealth, a nationally recognized not-for-profit, charitable health care organization based in Columbus, Ohio, have entered into a clinical affiliation that will enhance the high quality, affordable health care services they provide in central Ohio.

13 Jun 2011

Unique approach improves discharge disposition and older patient's outcomes

The rehospitalization of senior patients within 30 days of discharge from a skilled nursing facility (SNF) has risen dramatically in recent years, at an estimated annual cost of more than $17 billion.

13 Jun 2011

Only 35% of anaesthesiologists carry out cardiac output monitoring during high-risk surgery

Only 35% of anaesthesiologists are carrying out a simple procedure during high-risk surgery that can make a significant impact on how well patients recover from their operations, according to new research presented today at the European Anaesthesiology Congress in Amsterdam.

13 Jun 2011

New vaccines on the horizon

In a report published in The Lancet, researchers say there is the potential to develop 20 new or improved vaccines over the next decade. They emphasize that funding is crucial - but so is trust and confidence in vaccines. It is said that AIDS and malaria vaccines as the most important areas for research. Authors further suggest that neglected tropical diseases, such as leprosy, should also be investigated.

9 Jun 2011

University of Perugia researcher to lead BioNanoFilter European clinical trial on Group B Strep

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today its BioNanoFilter (BNF) technology will undergo a clinical trial, led by Dr. Gian Carlo Di Renzo of the University of Perugia in Italy.

7 Jun 2011

Several drug makers plan to lower prices of vaccines for GAVI purchase

Several pharmaceutical companies have pledged to lower the prices of vaccines against childhood illnesses ahead of the GAVI Alliance conference in London next week, the Guardian reports (Quinn, 6/6).

6 Jun 2011

Pneumonia News and Research

Latest Pneumonia News and Research

Wildfire exposure may increase risk of heart failure

Researchers identify new component of plague causing bacterium that can be used as a vaccine

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

'Copilots' for physicians in intensive care units could reduce mortality rates

U.S. FDA approves generic Levaquin for treatment of bacterial infections

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Serious RSV infections may occur in previously healthy infants and children

High proportion of men with prostate cancer die from the disease

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

Billions committed for children’s vaccines

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

Unique approach improves discharge disposition and older patient's outcomes

Only 35% of anaesthesiologists carry out cardiac output monitoring during high-risk surgery

New vaccines on the horizon

University of Perugia researcher to lead BioNanoFilter European clinical trial on Group B Strep

Several drug makers plan to lower prices of vaccines for GAVI purchase

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Pneumonia News and Research

Latest Pneumonia News and Research

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in